<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04990362</url>
  </required_header>
  <id_info>
    <org_study_id>69/5-6-2021</org_study_id>
    <nct_id>NCT04990362</nct_id>
  </id_info>
  <brief_title>Effects of Pomegranate Seed Oil and Mediterranean Diet on MCI</brief_title>
  <official_title>Effects of Pomegranate Seed Oil and Mediterranean Diet at Motor Skills and Cognitive Abilities in Mild Cognitive Impairment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aristotle University Of Thessaloniki</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Greek Alzheimer's Association and Related Disorders</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aristotle University Of Thessaloniki</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A double-blind clinical trial of pomegranate oil and Mediterranean diet that will be carried&#xD;
      out on 60 patients with Mild Cognitive Impairment (MCI) and APOE ε3 and ε4 allele.&#xD;
&#xD;
      The aim of the research is to examine if the Mediterranean diet with pomegranate oil and&#xD;
      without it can bring positive changes in patients with MCI in terms of motor and cognitive&#xD;
      skills.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES OF THE TRIAL&#xD;
&#xD;
      The objectives of this study are:&#xD;
&#xD;
      To investigate the efficacy of Mediterranean diet and Pomegranate oil as a disease course&#xD;
      modifying treatment for MCI.&#xD;
&#xD;
      STUDY DESIGN This is a Greek, controlled double-blind trial of two compared groups, one with&#xD;
      Mediterranean diet and one with Mediterranean diet and pomegranate oil. Qualifying patients&#xD;
      will be assigned to receive 0.15 mL of pomegranate oil every day with Mediterranean diet at&#xD;
      one group and at the other group will not. A Mediterranean dietary protocol will be given on&#xD;
      a daily basis for 12 months at both groups.&#xD;
&#xD;
      Duration The total study duration will be 12 months. The recruitment will be about 6 months&#xD;
      and the statistics and the preparation of the paper other 6 months.&#xD;
&#xD;
      Number of Subjects:&#xD;
&#xD;
      Sixty (60) subjects total will be enrolled.; Thirty (30) in the A group (Pomegranate oil +&#xD;
      Mediterranean Diet); Thirty (30) in the B Group (Mediterranean Diet).&#xD;
&#xD;
      Patient identification:&#xD;
&#xD;
      Initials (First initial of first name and First initial of surname), date of birth and&#xD;
      Patient Identification Number from database empedocles.&#xD;
&#xD;
      Eligibility Screening Form (ESF) : Checklist of inclusion and exclusion criteria Eligibility&#xD;
      Statement: for patients found to be ineligible, the reason for ineligibility must be stated&#xD;
      and Written informed consent will be obtained from the subjects which are eligible. The&#xD;
      informed consent form must be co-signed by the physician. The nature of the study and the&#xD;
      potential risks associated with the trial will be explained to all subjects- candidates and&#xD;
      their responsible informants.&#xD;
&#xD;
      Signature and date: the ESF may be completed by a research assistant but it is required that&#xD;
      the principal investigator/study clinician sign and date the ESF to verify eligibility of the&#xD;
      patient for inclusion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neuropsychological Assessment</measure>
    <time_frame>baseline,12 months</time_frame>
    <description>Measurements to Assess General Cognitive Function Changes in Mini-Mental State Examination (MMSE) score Score scale:0-30,cut off:24</description>
  </primary_outcome>
  <primary_outcome>
    <measure>FUCAS</measure>
    <time_frame>baseline,12 months</time_frame>
    <description>Measurements to Assess Daily Functionality Changes in Functional cognitive assessment scale (FUCAS) score Score scale:42-126,cut off:42</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Letter &amp; Category Fluency Test</measure>
    <time_frame>baseline,12 months</time_frame>
    <description>Measurement to Assess Verbal Fluency and Learning Changes in the Letter &amp; Category Fluency Test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CDR</measure>
    <time_frame>baseline,12 months</time_frame>
    <description>Measurements to Assess General Cognitive Function Changes in Global Clinical Dementia Rating (CDR)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MoCA</measure>
    <time_frame>baseline,12 months</time_frame>
    <description>Measurements to Assess General Cognitive Function Changes in Montreal Cognitive Assessment (MoCA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CANTAB</measure>
    <time_frame>baseline,12 months</time_frame>
    <description>Measurements to Assess General Cognitive Function Changes in Cambridge Neuropsychological Test Automated Battery (CANTAB)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clock Drawing test</measure>
    <time_frame>baseline,12 months</time_frame>
    <description>Measurements to Assess General Cognitive Function Changes in the Clock Drawing test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Logical Memory test</measure>
    <time_frame>baseline,12 months</time_frame>
    <description>Measurements to Assess General Cognitive Function Changes in the Logical Memory test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Digit Span Forward &amp; Backward test</measure>
    <time_frame>baseline,12 months</time_frame>
    <description>Measurements to Assess General Cognitive Function Changes in the Digit Span Forward &amp; Backward test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>WAIS-R Digit Symbol</measure>
    <time_frame>baseline,12 months</time_frame>
    <description>Measurements to Assess General Cognitive Function Changes in the WAIS-R Digit Symbol Substitution Test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TMT part A and B</measure>
    <time_frame>baseline,12 months</time_frame>
    <description>Measurements to Assess General Cognitive Function Changes in the Trail Making Test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ADASCog</measure>
    <time_frame>baseline,12 months</time_frame>
    <description>Measurements to Assess Daily Functionality Changes in Alzheimer's Disease Assessment Scale-Cognitive (ADASCog)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional Rating Scale for Dementia</measure>
    <time_frame>baseline,12 months</time_frame>
    <description>Measurements to Assess Daily Functionality Changes in Functional Rating Scale for Dementia (FRSSD)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Auditory Verbal Learning Test</measure>
    <time_frame>baseline,12 months</time_frame>
    <description>Measurement to Assess Verbal Fluency and Learning Changes in the Auditory Verbal Learning Test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Boston Naming Test</measure>
    <time_frame>baseline,12 months</time_frame>
    <description>Measurement to Assess Verbal Fluency and Learning Changes in the Boston Naming Test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fullerton Functional Test</measure>
    <time_frame>baseline,12 months</time_frame>
    <description>Measurement to Assess Physical Abilities</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>MD + Seed oil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pomegranate oil + Mediterranean Diet 30 patients Mediterranean dietary protocol Dietary Supplement: Pomegranate oil in a glass bottle of 30ml Dietary Supplement: Mediterranean dietary protocol&#xD;
Intervention:&#xD;
Mediterranean diet, Pomegranate oil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mediterranean Diet 30 patients Mediterranean dietary protocol Dietary Supplement: Mediterranean dietary protocol Intervention: Mediterranean diet</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Pomegranate oil, Mediterranean Diet</intervention_name>
    <description>Dietary Supplement: Pomegranate oil in a glass bottle of 0.15ml per day +Mediterranean dietary protocol Dietary Supplement: Mediterranean dietary protocol</description>
    <arm_group_label>MD + Seed oil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Mediterranean Diet</intervention_name>
    <description>Dietary Supplement: Mediterranean dietary protocol</description>
    <arm_group_label>MD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Mild Cognitive Impairment&#xD;
&#xD;
          -  Carry APOE ε3 or ε4 genes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Dementia&#xD;
&#xD;
          -  Patients who receive medication for memory or depression&#xD;
&#xD;
          -  Patients who do not carry APOE ε3 or ε4 genes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Magda Tsolaki, MD PhD Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aristotle University Of Thessaloniki</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Magda Tsolaki, MD PhD Prof.</last_name>
    <phone>0030 2310 2411 56</phone>
    <email>tsolakim1@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Panagiotis Papadimitriou, BSc</last_name>
    <phone>00302314020236</phone>
    <email>7panpap7@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Alzheimer Hellas</name>
      <address>
        <city>Thessaloníki</city>
        <state>Thessaloniki</state>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 26, 2021</study_first_submitted>
  <study_first_submitted_qc>July 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 4, 2021</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aristotle University Of Thessaloniki</investigator_affiliation>
    <investigator_full_name>Magda Tsolaki</investigator_full_name>
    <investigator_title>Professor of Neurology, Medical School, Aristotle University of Thessaloniki Affiliation: Aristotle University of Thessaloniki</investigator_title>
  </responsible_party>
  <keyword>Mild Cognitive Impairment</keyword>
  <keyword>Cognition</keyword>
  <keyword>Mental Health</keyword>
  <keyword>APOE</keyword>
  <keyword>ε3/ε3</keyword>
  <keyword>ε3/ε2</keyword>
  <keyword>ε3/ε4</keyword>
  <keyword>ε2/ε4</keyword>
  <keyword>ε4/ε4</keyword>
  <keyword>Pomegranate oil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Participants' personal data will not be shared with other researchers</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

